Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte

Cardiovascular Research

Volumn 38, Issue 1, 1998, Pages 198-205

  Tahara, Atsuo ^a   Tomura, Yuichi ^a   Wada, Koh ichi ^a   Kusayama, Toshiyuki ^a   Tsukada, Junko ^a   Ishii, Noe ^a   Yatsu, Takeyuki ^a   Uchida, Wataru ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cardiomyocytes; Rat; V(IA) receptor; Vasopressin; Vasopressin receptor antagonists; Vasopressin receptors; YM087

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ARGIPRESSIN; ARGIPRESSIN[1 (3,3 CYCLOPENTAMETHYLENE 3 MERCAPTOPROPIONIC ACID) 2 (O METHYLTYROSINE)]; CALCIUM ION; CONIVAPTAN; MITOGEN ACTIVATED PROTEIN KINASE; MOZAVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; HEART CELL CULTURE; HEART HYPERTROPHY; HEART MUSCLE CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ARGININE VASOPRESSIN; BENZAZEPINES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM; CELLS, CULTURED; LEUCINE; MYOCARDIUM; PIPERIDINES; PROTEIN BIOSYNTHESIS; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; STIMULATION, CHEMICAL; THYMIDINE;

EID: 0032051870     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00324-6     Document Type: Article

References (45)

1. [1] Johnston CI. Vasopressin in circulatory control and hypertension. J Hypertens 1985;3:557-569.
2. [2] Gavras H, Gavras I. Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. J Hypertens 1989;7:601-606.
3. [3] Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993;73:439-447.
4. [4] Hirata Y, Fukuda Y, Yoshimi H, Emori T, Shichiri M, Marumo F. Specific receptor for endothelin in cultured rat cardiomyocytes. Biochem Biophys Res Commun 1989;160:1438-1444.
5. 2+] in the neonatal rat cardiomyocyte. Circ Res 1991;69:239-245.
6. [6] Michell RH, Kirk CJ, Billah MM. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 1979;7:861-865.
7. i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes. Am J Physiol 1994;266:H597-H605.
8. 2-vasopressinergic receptors. Am J Physiol 1988;255:H261-H265.
9. [9] Laszlo FA, Laszlo F Jr., De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 1991;43:73-108.
10. [10] Manning M, Sawyer WH. Design and uses of selective agonistic and antagonistic analogs of the neuropeptides oxytocin and vasopressin. Trends Neurosci 1984;7:8-9.
11. [11] Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991;252:572-574.
12. 1 receptor of rat, rhesus and human tissues. Life Sci 1992;50:1953-1958.
13. 2 receptor antagonist. Br J Pharmacol 1992;105:787-791.
14. 1a receptors. J Clin Invest 1993;92:224-231.
15. 2 receptor antagonist. J Clin Invest 1996;98:2729-2738.
16. 2 receptor AVP antagonist in human heart failure. Nephrology 1997;3:S15.
17. 1 antagonist (OPC-21268) on vascular action of vasopressin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun 1991;178:707-712.
18. 1 antagonist OPC-21268. Hypertension 1994;23:217-222.
19. 1a antagonist, on human vascular smooth muscle cells. Am J Physiol 1995;268:H404-H410.
20. 1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells. Biochem Pharmacol 1994;47:633-641.
21. 2+ concentration in vascular and cardiac myocytes. Hypertension 1992;19:730-733.
22. [22] Yoshitomi K, Naruse M, Hanaoka K, Yamamura Y, Imai M, Kurokawa K. Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct. Kidney Int 1996;55:S177-S182.
23. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997;282:301-308.
24. 2 receptor antagonist, in dogs. Eur J Pharmacol 1997;321:225-230.
25. [25] Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Circ Res 1982;50:101-116.
26. [26] Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, Torti FM. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990;87:4275-4279.
27. [27] Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
28. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450.
29. 8 vasopressin receptor with a radiolabelled V1-selective antagonist. J Recept Res 1989;9:1-18.
30. 1) receptor characteristics in rat aortic smooth muscle cells. Am J Physiol 1991;261:H1927-H1936.
31. [31] Thibonnier M. Signal transduction of V1-vascular vasopressin receptors. Regul Pept 1992;38:1-11.
32. 5Tyr(Me)AVP] in mesangial cells. Biochem Biophys Res Commun 1993;193:738-743.
33. [33] Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993;92:398-403.
34. [34] Shubeita HE, Martinson EA, Van Bilsen M, Chien KR, Brown JH. Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by protein kinase C in neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1992;89:1305-1309.
35. [35] Kariya K, Karns LR, Simpson PC. Expression of a constitutively activated mutant of the beta-isozyme of protein kinase C in cardiac myocytes stimulates the promoter of the beta-myosin heavy chain isogene. J Biol Chem 1991;266:10023-10026.
36. [36] Granot Y, Van Putten V, Schrier RW. Vasopressin dependent tyrosine phosphorylation of a 38 kDa protein in human platelets. Biochem Biophys Res Commun 1990;168:566-573.
37. [37] Pelech SL, Sanghera JS. Mitogen-activated protein kinases: versatile transducers for cell signaling. Trends Biochem Sci 1992;17:233-238.
38. [38] Granot Y, Erikson E, Fridman H, Van Putten V, Williams B, Schrier RW, Maller JL. Direct evidence for tyrosine and threonine phosphorylation and activation of mitogen-activated protein kinase by vasopressin in cultured rat vascular smooth muscle cells. J Biol Chem 1993;268:9564-9569.
39. [39] Russel WE, Bucher NL. Vasopressin modulates liver regeneration in the Brattleboro rat. Am J Physiol 1983;245:G321-G324.
40. [40] Rozengurt E, Legg A, Pettican P. Vasopressin stimulation of mouse 3T3 cell growth. Proc Natl Acad Sci USA 1979;76:1284-1287.
41. [41] Kim JK, Michel JB, Soubrier F, Durr J, Corvol P, Schrier RW. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int 1990;38:818-822.
42. [42] Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-266.
43. [43] Goldsmith SR, Francis GS, Cowley AW Jr., Goldenberg IF, Cohn JN. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986;8:779-783.
44. [44] Arnolda L, McGrath BP, Johnston CI. Vasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure. Cardiovasc Res 1991;25:68-72.
45. [45] Nicod P, Waeber B, Bussien JP, Goy JJ, Turini G, Nussberger J, Hofbauer KG, Brunner HR. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol 1985;55:1043-1047.